Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
J Diabetes Complications ; 34(3): 107480, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-31902653

RESUMO

AIMS: To examine whether addition of amlodipine (5 mg)/atorvastatin (10 mg) A/A to Therapeutic Lifestyle change intervention (TLC) would beneficially modulate Metabolic Syndrome (MetS) and oxidized low-density lipoprotein (Ox-LDL) levels. METHODS: Patients with MetS (n = 53) were randomized to TLC + placebo or TLC + A/A for 12 months. Anthropometric measurements, blood pressure (BP), lipid profile, plasma Ox-LDL, and area under the curve of free fatty acid (AUCFFA) during oral glucose tolerance test, a marker of adipose tissue health, were assessed before and after the intervention. RESULTS: Twenty-six patients completed the study with an overall improvement of MetS (p = 0.02). TLC + placebo was beneficial in reversing MetS comparable to TLC + A/A (54% vs. 39%; p = 0.08). Both treatments decreased systolic BP (p ≤ 0.01). TLC + A/A also decreased diastolic BP and triglyceride levels. The changes in Ox-LDL levels directly correlated with changes in weight in the TLC-placebo group (r = 0.64; p = 0.04). AUCFFA determined the loss of fat mass (r = 0.472, p = 0.03). CONCLUSIONS: 1) Addition of A/A has the advantage of improving the lipid profile and BP; but TLC alone was comparable to TLC + A/A in improving MetS; 2) weight change determines the TLC-associated change in Ox-LDL levels; and 3) AT metabolic health is a significant predictor of TLC-associated loss of body fat mass.


Assuntos
Anlodipino/uso terapêutico , Terapia Comportamental/métodos , Ácidos Heptanoicos/uso terapêutico , Síndrome Metabólica/terapia , Pirróis/uso terapêutico , Adulto , Idoso , Anlodipino/administração & dosagem , Atorvastatina/administração & dosagem , Biomarcadores/sangue , Pressão Sanguínea/fisiologia , Fatores de Risco Cardiometabólico , Terapia Combinada , Combinação de Medicamentos , Feminino , Humanos , Estilo de Vida , Lipídeos/sangue , Lipoproteínas LDL/sangue , Masculino , Síndrome Metabólica/sangue , Síndrome Metabólica/fisiopatologia , Pessoa de Meia-Idade , Estresse Oxidativo/fisiologia , Placebos , Comportamento de Redução do Risco
2.
Am J Physiol Regul Integr Comp Physiol ; 307(3): R332-9, 2014 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-24848362

RESUMO

The aim of this study was to investigate effects and mechanisms of electroacupuncture (EA) on blood glucose and insulin sensitivity in mice fed a high-fat diet. Both wild-type (WT) and adipose ectonucleotide pyrophosphate phosphodiesterase (ENPP1) transgenic (TG) mice were fed a high-fat diet for 12 wk; for each mouse, an intraperitoneal glucose tolerance test (IPGTT) and insulin tolerance test (ITT) were performed with or without EA at abdomen or auricular areas. A high-fat diet-induced insulin resistance in both WT and TG mice. In the WT mice, EA at 3 Hz and 15 Hz, but not at 1 Hz or 100 Hz, via CV4+CV12 significantly reduced postprandial glucose levels; EA at 3 Hz was most potent. The glucose level was reduced by 61.7% at 60 min and 74.5% at 120 min with EA at 3 Hz (all P < 0.001 vs. control). Similar hypoglycemic effect was noted in the TG mice. On the contrary, EA at auricular points increased postprandial glucose level (P < 0.03). 4). EA at 3 Hz via CV4+CV12 significantly enhanced the decrease of blood glucose after insulin injection, suggesting improvement of insulin sensitivity. Plasma free fatty acid was significantly suppressed by 42.5% at 15 min and 50.8% at 30 min with EA (P < 0.01) in both WT and TG mice. EA improves glucose tolerance in both WT and TG mice fed a high-fat diet, and the effect is associated with stimulation parameters and acupoints and is probably attributed to the reduction of free fatty acid.


Assuntos
Glicemia/metabolismo , Eletroacupuntura , Hipoglicemia/metabolismo , Hipoglicemia/fisiopatologia , Resistência à Insulina/fisiologia , Animais , Glicemia/efeitos dos fármacos , Dieta Hiperlipídica , Gorduras na Dieta/farmacologia , Modelos Animais de Doenças , Ácidos Graxos não Esterificados/metabolismo , Feminino , Insulina/farmacologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Diester Fosfórico Hidrolases/genética , Diester Fosfórico Hidrolases/metabolismo , Período Pós-Prandial , Pirofosfatases/genética , Pirofosfatases/metabolismo
3.
Diabetes Care ; 32(6): 990-5, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19279300

RESUMO

OBJECTIVE: High levels of dietary fiber, especially soluble fiber, are recommended to lower serum cholesterol levels and improve glycemic control in patients with type 2 diabetes. It is not clear, however, how high levels of fiber affect mineral balance. RESEARCH DESIGN AND METHODS: In a randomized crossover study, 13 patients with type 2 diabetes were fed a high-fiber (50 g total and 25 g soluble fiber) and a moderate-fiber (24 g total and 8 g soluble fiber) diet of the same energy, macronutrient, calcium, magnesium, and phosphorus content for 6 weeks each. Intestinal calcium absorption was determined by fecal recovery of (47)Ca. Stool weight and mineral content were assessed during 3 days, and 24-h urinary mineral content and serum chemistry were assessed over 5 days at the end of each phase. The results were compared by repeated-measures ANOVA. RESULTS: Compared with the moderate-fiber diet, the high-fiber diet increased stool weight (165 +/- 53 vs. 216 +/- 63 g/day, P = 0.02) and reduced 24-h urinary calcium (3.3 +/- 1.7 vs. 2.4 +/- 1.2 mmol/day, P = 0.003) and phosphorus (29.2 +/- 5.5 vs. 26.0 +/- 3.2 mmol/day, P = 0.003) excretion and serum calcium concentration (2.33 +/- 0.06 vs. 2.29 +/- 0.07 mmol/l, P = 0.04). Calcium absorption, stool calcium, magnesium, and phosphorus content and serum phosphorus concentration were not significantly different with the two diets. CONCLUSIONS: A high-fiber diet rich in soluble fiber has a small impact on calcium and phosphorus balance in subjects with type 2 diabetes. It may be prudent to ensure adequate intake of calcium and other minerals in individuals consuming a high-fiber diet.


Assuntos
Cálcio da Dieta , Cálcio/sangue , Diabetes Mellitus Tipo 2/sangue , Dieta/estatística & dados numéricos , Fibras na Dieta , Análise Química do Sangue , Cálcio da Dieta/metabolismo , Estudos Cross-Over , Humanos , Absorção Intestinal , Minerais/sangue , Minerais/urina , Fósforo/sangue , Urinálise
4.
J Investig Med ; 56(5): 780-5, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18525453

RESUMO

BACKGROUND: Because dietary N-3 fatty acids reduce plasma triglycerides, they may also decrease hepatic triglyceride content. If so, N-3 fatty acids might constitute a therapy for fatty liver. METHODS: Twenty-two subjects were recruited into a study designed to test the effects of N-3 fatty acids on liver fat content. Seventeen completed the trial that had a sequential design of 4-week placebo followed by an 8-week treatment with 9 g/d of fish oil. Liver fat was measured during placebo and treatment by magnetic resonance spectroscopy. Compliance was assessed by capsule count at the end of each study phase and measurement of fatty acid composition in plasma triglyceride and phospholipid. Plasma lipoproteins and adiponectin were also measured. RESULTS: Treatment with fish oils reduced significantly levels of plasma triglyceride by 46% (P <.03), very low-density lipoprotein + intermediate density lipoprotein cholesterol by 21% (P <.03), total apolipoprotein B by 15% (P <.03). In contrast to the changes in plasma triglycerides, hepatic triglyceride content was not significantly reduced by fish oil treatment. CONCLUSIONS: N-3 fatty acids at high doses lower plasma triglyceride levels, but there are no significant decreases in hepatic content of triglyceride for the group as a whole. Whereas the triglyceride lowering is uniform, the liver response is more variable.


Assuntos
Ácidos Graxos Ômega-3/administração & dosagem , Fígado/efeitos dos fármacos , Fígado/metabolismo , Triglicerídeos/metabolismo , Adulto , Fígado Gorduroso/sangue , Fígado Gorduroso/dietoterapia , Fígado Gorduroso/metabolismo , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Triglicerídeos/sangue
5.
Am J Med ; 113 Suppl 9B: 25S-29S, 2002 Dec 30.
Artigo em Inglês | MEDLINE | ID: mdl-12566135

RESUMO

Two cholesterol-raising fatty acids in the diet, saturated fatty acids and trans fatty acids, increase the serum low-density lipoprotein cholesterol concentration. This fact justifies the recommendation of a reduced intake of cholesterol-raising fatty acids. Emerging data suggest that diets higher in unsaturated fatty acids, particularly monounsaturated fatty acids, have several advantages over high-carbohydrate intakes. This advantage appears to hold, particularly for populations having a high prevalence of insulin resistance, such as the US population. If the US public were to modify its eating habits in the direction of better weight control and more exercise, higher intakes of carbohydrate might be better tolerated. At the same time, the experience with the Mediterranean population reveals that in healthier populations, diets relatively high in unsaturated fatty acids are well tolerated and are associated with a low prevalence of both coronary heart disease and type 2 diabetes.


Assuntos
Dieta , Gorduras na Dieta/administração & dosagem , Síndrome Metabólica/etiologia , Glicemia/metabolismo , Carboidratos da Dieta/administração & dosagem , Ácidos Graxos Insaturados/administração & dosagem , Humanos , Hiperlipidemias/complicações , Resistência à Insulina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA